| | 71-58-9 Basic information More.. |
| Product Name: | Medroxyprogesterone Acetate | | Synonyms: | MEDROXYPROGESTERONE ACETATE, FOR PERFORMANCE TEST EP STANDARD;Medroxyprogesterone Acetate, Micronized;17α-Acetoxy-6α-methylprogesterone, 6α-Methyl-17α-acetoxyprogesterone, 6α-Methyl-17α-hydroxyprogesterone acetate, Depo-provera, 17α-Hydroxy-6α-methyl-4-pregnene-3,20-dione 17-acetate;(6-alpha)-Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl;Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6.alpha.)-;17α-acetoxy-6α-methylprogesterone;6a-methyl-17a-acetoxyprogesterone;MEDROXYPROGESTERONEACETATE,MICRONIZED,USP | | CAS: | 71-58-9 | | MF: | C24H34O4 | | MW: | 386.52 | | EINECS: | 200-757-9 | | Mol File: | 71-58-9.mol |  |
Use
A depot preparation containing 150 mg medroxyprogesterone
acetate was introduced over 20 years ago for use as a long-acting injectable
contraceptive. Subsequently, positive results of carcinogenicity studies carried out
in beagle bitches led to refusal of registration in the United States. These findings
were later considered irrelevant to contraceptive use in women and the drug was
approved by the Food and Drug Administration. Menstrual irregularities are the
most common adverse effect associated with depot medroxyprogesterone acetate.
Risk-benefit judgements differ significantly from country to country, having regard
to differing national circumstances. The preparation is, however, widely available
and is included in the WHO Model List of Essential Drugs.
(Reference: (WHTAC4) The Use of Essential Drugs, 4th Report of the WHO Expert
Committee, 796, , 1990)
|
|
71-58-9
Recommend Suppliers |
|